Kornimate/medical-research-clean huggingface dataset:
eye drop use in glaucoma patients through patient surveys and video observations

Conditions: Glaucoma; Dry Eye Syndrome; Conjunctivitis

Summary: this study will be used to evaluate how patients put eye drops in their eyes and any problems that may arise from this activity. the information gathered will help identify common problems patients are having with putting in their eye medications. then doctors can be better informed about the issues and provide better advice to their patients to overcome these problems.

approximately 100 patients will take part in a one time procedure and survey as part of this project. after appropriate consent patients are asked to complete a short 2 page survey about themselves and their eye drops. then a video recording will be made of the patient instilling eye drops in their habitual manner. the eye drops used will be sterile saline placed in either travatan-like or systane bottles to simulate the corresponding prescribed medication. the videos will be graded for instillation technique and combined with scoring of survey answers. patients will be asked to instill the drops to their left eye with their dominant hand as we expect this to be most difficult. patients with severe (\>20/200) vision loss will instill drops into their better seeing eye.

Eligibility criteria:
inclusion criteria: * currently using topical glaucoma medications

Keywords: eyedrops compliance glaucoma medications adherence
the effect of intelligent exercise on vascular function, grip strength and adherence in patients with avf after surgery

Conditions: Arteriovenous Fistula; Isometric Exercise

Summary: isometric exercise can effectively promote the vascular function of arteriovenous fistula and increase hand grip strength, but patients needs to perform isometric exercises patiently. the purpose of this study want investigate the effect of using individual intelligent devices for forearm isometric exercise training on the increase of arteriovenous fistula vascular function and hand grip strength, and the improvement of patients' adherence with forearm isometric exercise.

an arteriovenous fistula(avf) is the most preferred and safe vascular access for long-term hemodialysis patients. isometric exercise can effectively promote the vascular function of avf and increase hand grip strength, but patients needs to perform isometric exercises patiently. however, the patient's disease factors, muscle soreness caused by the exercise process, etc., may easily prevent the patient from effectively performing isometric exercise every day.this study will be the first isometric exercise training intervention program for eight weeks after avf surgery with an intelligent device in taiwan. investigators expect to promote the vascular function of avf and increase hand grip strength, as well as improve participant' adherence performance after the re-intervention protocol. to construct an intelligent forearm isometric exercise, as a reference for clinical care guidance.

Eligibility criteria:
inclusion criteria: * age ≥ 20 years old * regular follow-up in the nephrology clinic * diagnosed with chronic kidney disease at stage 5 (or 5d) * expect to do the first autologous arteriovenous fistula surgery exclusion criteria: * not the first autologous arteriovenous fistula surgery * have undergone percutaneous transluminal angioplasty in the arm receiving autologous arteriovenous fistula * have undergone orthopedic disease-related surgery in the arm receiving autologous arteriovenous fistula * have been cardiovascular events within the past 3 months * have been heart function left ventricular ejection fraction within the past 3 months \<30%.

Keywords: vascular function muscle strength adherence
kinematic parameters to predict knee diseases.

Conditions: Knee Injuries; Knee Arthritis

Summary: there is no study to explore the prediction of knee diseases using kinematic parameters of knee during gait. the aim of this study is to explore the possibility of predicting knee diseases by gait parameters.


Eligibility criteria:
inclusion criteria: 1. age\> 18 years 2. body mass index\<30; 3. confirmed radiographically or by surgery to have knee injuries/arthritis; 4. knee pain in their knees at least one months; 5. able to walk unaided exclusion criteria: 1. history of other lower limbs' surgery/injuries/arthritis (hip or ankle); 2. corticosteroid or sodium hyaluronate injection within 6 months; 3. neuropathic arthropathy or rheumatoid arthritis; 4. any other muscular or neurological diseases that affected the condition of the lower limbs; 5. unable to walk independently; 6. history of heart disease; 7. body mass index\> 30; 8. age\> 90 years; 9. unable to finish the procedure

Keywords: knee gait injuries arthritis
a clinical study to evaluate the safety and pharmacokinetics of ckd-344 in healthy volunteers

Conditions: Anticoagulant

Summary: a clinical trial to evaluate the pharmacokinetics and safety of ckd-344

a phase 1 clinical trial to evaluate the safety and pharmacokinetics in healthy adult volunteers after administration of ckd-344.

Eligibility criteria:
inclusion criteria: 1. healthy adult volunteers aged ≥ 19 years 2. weight ≥60kg, with calculated body mass index(bmi) of 18 to 30 kg/m2 3. those who have no congenital diseases or chronic diseases and have no abnormal symptoms or findings. 4. those who are eligible for clinical trials based on laboratory (hematology, blood coagulation, blood chemistry, serology, urinalysis) at screening. 5. those who agree to contraception during the participation of clinical trial. 6. those who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial. exclusion criteria: 1. those who has a medical evidence or a history of clinically significant gastrointestinal, cardiovascular, endocrine, pulmonary, hematological, infective disease, renal, urinary, psychiatric, neurologic, skeletomuscular, immune, etc. 2. those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery. 3. those who had taken prescription or nonprescription drugs within 10 days prior to the first dose of investigational product. 4. those who received investigational products or participated in bioequivalence tests within 6 months before the first administration of clinical trial drugs. 5. those who donated whole blood within 8 weeks or blood components within 4 weeks prior to the first dose of the investigational product. 6. those who exceed an alcohol and cigarette consumption than below criteria. a. alcohol: man- 21 glasses/week, woman - 14 glasses/week b. smoking: 20 cigarettes/day 7. those who exceeds 2 times the upper limit of the reference range of ast(or alt) or 1.5 times the upper limit of the reference range of γ-gtp. 8. those who have hypersensitivity to the drug or the drug ingredient, such as anaphylactic reactions. 9. those who have specific disease(e.g. severe bleeding disorder, severe renal/hepatic disease, uncontrolled severe hypertension, etc.) 10. those who were deemed inappropriate to participate in the study by the investigator. 11. those who have a pregnant or nursing woman.
a phase i, single iv dose of pf-04360365 in adults with mild to moderate alzheimer's disease

Conditions: Alzheimer's Disease

Summary: the purpose of this study is determine whether a single iv dose of pf-04360365 is safe and well tolerated in adults with mild to moderate alzheimer's disease.


Eligibility criteria:
inclusion criteria: * male or females of non-childbearing potential, age 50-85 * diagnosis of probable alzheimer's disease, consistent with criteria from both: 1) national institute of neurological and communicable disease and stroke and alzheimer's disease and related disorders association (nincds-adrda); and 2)diagnostic and statistical manual of mental disorders (dsm iv) * mini-mental status exam score of 16-26 inclusive * rosen-modified hachinski ischemia score \< or = 4 exclusion criteria: * diagnosis or history of other dementia or neurodegenerative disorders * diagnosis or history of clinically significant cerebrovascular disease * specific findings on magnetic resonance imaging (mri): cortical infarct, micro hemorrhage, multiple white matter lacunes, extensive white matter abnormalities * history of autoimmune disorders * history of allergic or anaphylactic reactions
impact on reducing the incidence of low serum calcium by providing educational materials on the need to take daily supplemental calcium and vitamin d to patients with paget's disease treated with reclast®

Conditions: Paget's Disease of the Bone; Hypocalcemia

Summary: this study will evaluate the impact of investigator and patient education and educational materials to foster calcium and vitamin d supplementation to mitigate the potential for hypocalcemia post reclast® administration in patients with paget's disease of bone.


Eligibility criteria:
inclusion criteria: * written informed consent * as per currently approved reclast® package insert: exclusion criteria: - as per currently approved reclast® package insert:

Keywords: paget's hypocalcemia zoledronic acid serum calcium
bioavailability of gli/metxr (4/850 mg)

Conditions: Healthy

Summary: objective: the purpose of this study is to evaluate the oral bioavailability of the combination glimepiride/ extended release metformin (gli/metxr) (4/850mg) in healthy mexican volunteers in fasting conditions. methods: a prospective, longitudinal, open label, non randomized study, was performed, 24 volunteers were administrated with a single oral dose of gli/metxr (4/850 mg).

blood samples were collected over 30 hours. plasma concentration of both drugs were measured by using high-performance liquid chromatography (hplc). plasma concentration-time curves were plotted for each volunteer, and pharmacokinetic parameters (pk) were calculated. the pharmacokinetic parameters to be determined are: cmax, tmax, auc0-t, auc0-inf, tmr, ke, t1 / 2 of glimepiride and metformin adverse events were determined using clinical and laboratory test results, throughout the study. the statistical analysis will be descriptive for plasma concentrations with respect to time and the pharmacokinetic parameters of cmax, tmax, auc0-t, auc0-inf, tmr, ke, t1/2 of glimepiride and metformin.

Eligibility criteria:
inclusion criteria: * healthy mexican volunteers, considered healthy according to standard screening assessments * aged between 18 and 50 years old * body mass index (bmi) was 18 to 27.5 exclusion criteria: * those with a history or evidence of cardiovascular, renal, hepatic, gastrointestinal, neurologic, muscular, metabolic, or hematologic abnormality * any acute or chronic disease * any drug allergy and female volunteers positive to urinary pregnancy test or breastfeeding

Keywords: dm2 glimepiride metformin extended release
effects of unloader bracing in clinical outcome and cartilage physiology following microfracture of chondral defects

Conditions: Cartilage Loss; Microfracture

Summary: the study will examine clinical and radiographic outcomes of microfracture surgery (a common technique to address isolated areas of cartilage loss) in the knee used with or without unloader bracing. randomly selected patients will wear an unloader brace, which is designed to take pressure off the area of the knee which underwent repair, for several weeks after surgery. our hypothesis is that bracing may improve clinical and or radiographic outcomes. the surgery performed will be the same for all patients the length of follow up and schedule of post-operative mri will be the same for all patients. the only difference in groups will be presence of absence of brace wear.

the study will examine clinical and radiographic outcomes of microfracture surgery (a common technique to address isolated areas of cartilage loss) in the knee used with or without unloader bracing. radiographic outcome will be assessed via mri scans post-operatively. randomly selected patients will wear an unloader brace, which is designed to take pressure off the area of the knee which underwent repair, for several weeks after surgery. our hypothesis is that bracing may improve clinical and or radiographic outcomes. the surgery performed will be the same for all patients the length of follow up and schedule of post-operative mri will be the same for all patients. the only difference in groups will be presence of absence of brace wear.

Eligibility criteria:
inclusion criteria: * isolated chondral defect of medial or lateral femoral condyle 2cm squared or less * age 15-40 * neutral knee alignment exclusion criteria: * prior cartilage procedures performed in the same knee * other significant knee pathology including meniscus tears, ligament tears or inflammatory arthritis

Keywords: cartilage microfracture knee bracing
hla-haploidentical hematopoietic stem cell transplantation for children and adolescents with acute leukemia, myelodysplastic syndrome and solid tumors

Conditions: Acute Leukemia; Myelodysplastic Syndrome; Solid Tumors

Summary: rationale: conditioning with total body irradiation (tbi) and fludarabine, cyclophosphamide and anti-thymocyte globulin may induce the engraftment cross the immunologic barrier in the setting of hla-haploidentical allogeneic hematopoietic cell transplantation. in addition, t-cell depletion may contribute to prevent developing severe acute graft versus host disease (gvhd) in haploidentical transplantation. purpose: this phase i/ii trial is to evaluate the safety and efficacy of tbi, fludarabine, cyclophosphamide and antithymocyte globulin with t-cell depleted graft from haploidentical donors in treating patients with acute leukemia and myelodysplastic syndrome.


Eligibility criteria:
inclusion criteria 1. disease characteristics * acute lymphoblastic leukemia (first remission, high risk; beyond first remission; refractory) * acute myeloblastic leukemia (first remission, high risk; beyond first remission; refractory) * myelodysplastic syndrome * solid tumors (refractory/relapse) 2. no hla-identical family member or closely matched (8 or 7 of 8 hla-locus match) unrelated marrow donor available 3. hla-haploidentical related donor available exclusion criteria 1. active fungal infections 2. hiv positive 3. pregnant or nursing

Keywords: tbi fludarabine cd3 depletion children and adolescents haploidentical hematopoietic stem cell transplantation
efficacy and safety of lactoferrin in heart failure patients

Conditions: Heart Failure With Reduced Ejection Fraction

Summary: this study will be conducted to determine the efficacy and safety of lactoferrin versus oral iron versus lactoferrin plus oral iron as an add on therapy in reduced ejection fraction heart failure patients with iron deficiency. •patients will be randomly distributed into the three groups * all patients will be subjected to baseline data assessment * follow up after 12 weeks


Eligibility criteria:
inclusion criteria: 1. age: 18-65 years old. 2. chronic heart failure (\> 6 months duration) with reduced ejection fraction defined as lvef ≤ 40%. 3. nyha-class ii or iii or iv with stable symptoms for at least the past 3 months. 4. stabilized on beta blockers, renin-angiotensin system inhibitor (acei/arb) or angiotensin receptor-neprilysin inhibitors (arnis), mineralocorticoid receptor antagonists (mras) and sodium-glucose co-transporter 2 inhibitors (sglt2i) and diuretics as needed. 5. no dose changes of heart failure drugs during the last 2 weeks (exception: diuretics) 6. no introduction of a new heart failure drug class during the last 4 weeks. 7. iron deficiency: serum ferritin level of 15 to 100 ng/ml or a serum ferritin level of 101 to 299 ng/ml with transferrin saturation of less than 20%. exclusion criteria: * 1. arrythmia including atrial fibrillation (af) with poorly controlled ventricular rate at rest (\> 100 beats/min). 2. recent cardiac related hospitalizations in the past 3 months. 3. known active infection. 4. associated chronic medical disorder (chronic kidney disease (creatinine clearance \ 3× upper limit of normal), peptic ulcer or chronic blood loss). 5. associated bleeding disorder. 6. previous iron supplement in past 3 months. 7. anemia requiring blood transfusion (haemoglobin (hb) \< 7 g/dl). 8. folic acid or vitamin b12 deficiency. 9. hypersensitivity to lactoferrin or iron. 10. haemoglobinopathies (g6pd, thalassemia's, sickle cell disease). 11. pregnancy and lactation.

Keywords: lactoferrin oral iron reduced ejection fraction iron deficiency heart failure clinical trial
a study of the safety and efficacy of viagra in men with erectile dysfunction who do not self identify.

Conditions: Impotence

Summary: to compare the efficacy and safety of viagra (sildenafil citrate) vs. placebo for the treatment of men with ed and at least 1 prespecified risk factor who do not self identify as having ed.


Eligibility criteria:
inclusion criteria: * men who do not identify as having ed with documented ed * men 30 years of age and older * at least one prespecified risk factor for ed exclusion criteria: * subjects currently prescribed, taking and/or likely to be treated with nitrates or nitric oxide donors in any form on either a regular or intermittent basis * subjects with a known history of retinitis pigmentosa.
pilot study of nkg2d-ligand targeted car-nk cells in patients with metastatic solid tumours

Conditions: Solid Tumours

Summary: this is a single-centre, single arm, open-label pilot study to evaluate the safety and feasibility of car-nk cell treatment in subjects with metastatic solid tumours. autologous or allogeneic nk cells are transfected by mrna electroporation to prepare investigational car-nk cells with transiently enhanced specificity and activity against nkg2d-ligand expressing cancer cells.


Eligibility criteria:
inclusion criteria: 1. signed informed consent form must be obtained prior to any research procedure. 2. histologically or cytologically confirmed diagnosis of metastatic solid tumours 3. ecog performance status of 0-3; 4. adequate organ function defined as: anc≥1.0×10\^9/l, plt≥75×10\^9/l, alb≥25g/l, tbil≤1.5×uln, ast≤2.5×uln, alt≤2.5×uln, alp≤2.5×uln, cr≤1.5×uln; 5. the patient's own pbmcs or pbmcs from a biological parent or child who is willing to donate blood will be used to prepare car-nk cells. the parent or child should be ≥18 and ≤60 years old, and he or she is able to sign the informed consent for blood donation by himself/herself; 6. patients who won't benefit from surgery, or refuse surgical treatment; patients who won't benefit from chemotherapy, can't tolerate chemotherapy or refuse chemotherapy. 7. patients volunteer to participate in this study and sign the informed consent form for subjects; 8. blood donors sign the informed consent form for blood donors. 9. blood donors have negative test results for hiv, hbv and hcv; 10. if a subject or blood donor is a female of childbearing potential, she must have a negative urine pregnancy test result. exclusion criteria: 1. patients who are suffering from uncontrollable or active infectious diseases of the hematological system, cardiovascular system, respiratory system, digestive system, urinary system, or the endocrine system; 2. patients with immunologic deficiency or autoimmune diseases; 3. patients with severe hypersensitivity reactions; 4. patients received other forms of cellular therapies within the last 3 months; 5. patients received systemic steroids within the last 3 months; 6. patients who are breastfeeding or pregnant; 7. patients with brain metastases; 8. patients who have received an organ transplant.
evaluation of the efficacy of combination treatment with anakinra and pegsunercept in improving rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to evaluate the effect of anakinra (il-1 ra) and pegsunercept (peg stnf-ri) when they are used together in improving the signs and symptoms of rheumatoid arthritis. the study will also evaluate the safety of the combination treatment and its effect on slowing down bone and joint destruction due to rheumatoid arthritis. the results will be compared to the effect when only 1 single medication (anakinra or pegsunercept) is used.


Eligibility criteria:
* diagnosed with rheumatoid arthritis for at least 6 months * must be taking methotrexate \* must not take dmards other than methotrexate during the study * must not have had previous treatment with and protein-based tnf-alpha inhibitor (eg. etanercept, infliximab, peg stnf-ri, or d2e7) * must not have had previous treatment with anakinra * subjects must meet tender and swollen joint requirements at screening, have morning stiffness, and/or have elevated acute phase reactants
duoable for people with stroke and their caregivers

Conditions: Stroke; Stroke Ischemic; Stroke Hemorrhagic; Stroke Sequelae

Summary: the goal of this intervention study is to test whether a behavioral program that involves people with stroke and their caregivers is acceptable, safe, and can promote physically active lifestyles using enjoyable activities. participant duos (person with stroke and their caregiver) will be asked to complete assessments at 2 timepoints, wear an activity tracker, participate in 12 sessions with an occupational therapist, and complete an interview.


Eligibility criteria:
inclusion criteria (stroke participants): * stroke diagnosed more than 6 months ago * are 18 years of age or older * report ≥6 hours of sedentary behavior on a typical day or report engagement in ≤90 minutes of moderate-to-vigorous physical activity in the past week * reside in a community-based setting * are mobile within their home, with or without an assistive device and without physical assistance * are able to identify an eligible caregiver who will engage in assessments and intervention. inclusion criteria (caregiver participants): * are 18 years of age or older * report ≥6 hours of sedentary behavior on a typical day or report engagement in ≤90 minutes of moderate-to-vigorous physical activity in the past week * reside in a community-based setting * are mobile within their home, with or without an assistive device and without physical assistance exclusion criteria (stroke participants): * severe aphasia * are currently receiving chemotherapy or radiation treatments for cancer * have a medical diagnosis of neurodegenerative disorder (i.e., dementia, parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma) * received inpatient treatment for substance use disorder or psychiatric condition within the past 12 months * have a history of skin sensitivity related to adhesives * are pregnant or expecting to become pregnant in the next 2 months * reside in an institutional setting * are currently incarcerated exclusion criteria (caregiver participants): * have a history of skin sensitivity related to adhesives * are currently receiving chemotherapy or radiation treatments for cancer * have a medical diagnosis of neurodegenerative disorder (i.e., dementia, parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma) * received inpatient treatment for substance use disorder or psychiatric condition within the past 12 months * are pregnant or expecting to become pregnant in the next 2 months * reside in an institutional setting * are currently incarcerated

Keywords: lifestyle physical activity duoable able rehabilitation rehab occupational therapy physical therapy stroke